Zoetis Inc. (NYSE:ZTS) Shares Acquired by Brighton Jones LLC

Brighton Jones LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 180.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 4,629 shares of the company’s stock after buying an additional 2,978 shares during the period. Brighton Jones LLC’s holdings in Zoetis were worth $754,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Darwin Wealth Management LLC purchased a new position in Zoetis during the third quarter worth approximately $31,000. First Personal Financial Services acquired a new position in shares of Zoetis during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis during the 3rd quarter valued at approximately $33,000. Dunhill Financial LLC grew its stake in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the period. Finally, Quarry LP increased its holdings in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of several recent analyst reports. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, UBS Group started coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus price target of $211.89.

Zoetis Price Performance

NYSE:ZTS opened at $168.63 on Friday. The stock has a 50 day moving average price of $170.10 and a 200 day moving average price of $179.66. The stock has a market cap of $76.08 billion, a PE ratio of 31.70, a P/E/G ratio of 2.57 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the firm earned $1.36 EPS. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. Equities research analysts expect that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This is a boost from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. Zoetis’s dividend payout ratio is 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.